论文部分内容阅读
鉴于肝细胞癌能合成并分泌铁蛋白,其新生血管多孔,可使抗原抗体结合,组成一个“生物窗口”,故可利用放射标记的抗铁蛋白抗体针对肝细胞癌进行治疗。我们对105例患肝细胞癌病人进行广泛的研究,表明使用~(131)I抗铁蛋白抗体,应根据肿瘤的浸润程度和抗肿瘤效应的半衰期制定用药方案,首次用30mCi,第5天用20mCi;或用改良的剂量,首次为20mCi,第5天为10mCi。已
In view of the fact that hepatocellular carcinoma can synthesize and secrete ferritin, its neovascularization is porous, and antigens and antibodies can be combined to form a “biological window.” Therefore, radiolabeled anti-ferritin antibodies can be used to treat hepatocellular carcinoma. We carried out extensive studies on 105 patients with hepatocellular carcinoma and showed that the use of ~(131)I antiferritin antibody should be based on the extent of tumor infiltration and the half-life of anti-tumor effects. A drug regimen should be used for the first time, 30 mCi for the first 5 days. 20mCi; or with a modified dose, 20mCi for the first time and 10mCi for the fifth day. Already